Dynorphin-(1-13): The effect of in vivo treatment on opiate bindings in vitro

M. F. Jen; J. Garzon; H. H. Loh; N. M. Lee

doi:10.1016/0014-2999(83)90367-9

Dynorphin-(1-13): The effect of in vivo treatment on opiate bindings in vitro

M. F. Jen, J. Garzon, H. H. Loh, N. M. Lee

Pharmacology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Mice were injected intracerebroventricularly with different doses of dynorphin-(1-13) in vivo and decapitated after different intervals of time; crude P₂ fractions were then prepared and used for in vitro binding with [³H]dihydromorphine (DHM) and [³H][D-Ala²,D-Leu⁵]enkephalin. Dynorphin pretreatment was found to decrease DHM binding in vitro in a both time-dependent and dose-dependent manner. Its maximal effect lasted from 30 min to 3 h and recovery took place in 6-12 h. Analysis of the Scatchard plots showed that dynorphin decreased the number of high affinity-binding site for DHM, while K_D of this site was essentially unaltered. Neither B_max nor K_D of low affinity site were much affected. A similar decrease in high affinity B_max for DADLE was also obtained; however, the recovery was even more rapid. Extra washes of tissue did not significantly increase the binding, but preincubation of tissue in the presence of morphine reversed the dynorphin effect and increased DHM binding significantly to almost control levels. The probable mechanism of dynorphin in decreasing opiate receptor binding is discussed.

Original language	English (US)
Pages (from-to)	95-99
Number of pages	5
Journal	European Journal of Pharmacology
Volume	91
Issue number	1
DOIs	https://doi.org/10.1016/0014-2999(83)90367-9
State	Published - Jul 15 1983

Bibliographical note

Funding Information:
Supported by NIDA Grant DA-02643 and 5-K02-DA-00020 (NML) and 5-K02-DA-70554 (HHL). J. Garzon is a recipient of NIH Fellowship 705-TW-03080. The authors wish to thank Dr. Andrew P. Smith for his editorial assistance.

Keywords

Dihydromorphine
Dynorphin-(1-13)
In vitro
In vivo
Opiate binding
[D-Ala,D-Leu]enkephalin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/0014-2999(83)90367-9

OpenUrl availability

Full text

Cite this

@article{caecf0c3711c4422b4d1b75e82bc6de8,

title = "Dynorphin-(1-13): The effect of in vivo treatment on opiate bindings in vitro",

abstract = "Mice were injected intracerebroventricularly with different doses of dynorphin-(1-13) in vivo and decapitated after different intervals of time; crude P2 fractions were then prepared and used for in vitro binding with [3H]dihydromorphine (DHM) and [3H][D-Ala2,D-Leu5]enkephalin. Dynorphin pretreatment was found to decrease DHM binding in vitro in a both time-dependent and dose-dependent manner. Its maximal effect lasted from 30 min to 3 h and recovery took place in 6-12 h. Analysis of the Scatchard plots showed that dynorphin decreased the number of high affinity-binding site for DHM, while KD of this site was essentially unaltered. Neither Bmax nor KD of low affinity site were much affected. A similar decrease in high affinity Bmax for DADLE was also obtained; however, the recovery was even more rapid. Extra washes of tissue did not significantly increase the binding, but preincubation of tissue in the presence of morphine reversed the dynorphin effect and increased DHM binding significantly to almost control levels. The probable mechanism of dynorphin in decreasing opiate receptor binding is discussed.",

keywords = "Dihydromorphine, Dynorphin-(1-13), In vitro, In vivo, Opiate binding, [D-Ala,D-Leu]enkephalin",

author = "Jen, {M. F.} and J. Garzon and Loh, {H. H.} and Lee, {N. M.}",

note = "Funding Information: Supported by NIDA Grant DA-02643 and 5-K02-DA-00020 (NML) and 5-K02-DA-70554 (HHL). J. Garzon is a recipient of NIH Fellowship 705-TW-03080. The authors wish to thank Dr. Andrew P. Smith for his editorial assistance.",

year = "1983",

month = jul,

day = "15",

doi = "10.1016/0014-2999(83)90367-9",

language = "English (US)",

volume = "91",

pages = "95--99",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Dynorphin-(1-13)

T2 - The effect of in vivo treatment on opiate bindings in vitro

AU - Jen, M. F.

AU - Garzon, J.

AU - Loh, H. H.

AU - Lee, N. M.

N1 - Funding Information: Supported by NIDA Grant DA-02643 and 5-K02-DA-00020 (NML) and 5-K02-DA-70554 (HHL). J. Garzon is a recipient of NIH Fellowship 705-TW-03080. The authors wish to thank Dr. Andrew P. Smith for his editorial assistance.

PY - 1983/7/15

Y1 - 1983/7/15

N2 - Mice were injected intracerebroventricularly with different doses of dynorphin-(1-13) in vivo and decapitated after different intervals of time; crude P2 fractions were then prepared and used for in vitro binding with [3H]dihydromorphine (DHM) and [3H][D-Ala2,D-Leu5]enkephalin. Dynorphin pretreatment was found to decrease DHM binding in vitro in a both time-dependent and dose-dependent manner. Its maximal effect lasted from 30 min to 3 h and recovery took place in 6-12 h. Analysis of the Scatchard plots showed that dynorphin decreased the number of high affinity-binding site for DHM, while KD of this site was essentially unaltered. Neither Bmax nor KD of low affinity site were much affected. A similar decrease in high affinity Bmax for DADLE was also obtained; however, the recovery was even more rapid. Extra washes of tissue did not significantly increase the binding, but preincubation of tissue in the presence of morphine reversed the dynorphin effect and increased DHM binding significantly to almost control levels. The probable mechanism of dynorphin in decreasing opiate receptor binding is discussed.

AB - Mice were injected intracerebroventricularly with different doses of dynorphin-(1-13) in vivo and decapitated after different intervals of time; crude P2 fractions were then prepared and used for in vitro binding with [3H]dihydromorphine (DHM) and [3H][D-Ala2,D-Leu5]enkephalin. Dynorphin pretreatment was found to decrease DHM binding in vitro in a both time-dependent and dose-dependent manner. Its maximal effect lasted from 30 min to 3 h and recovery took place in 6-12 h. Analysis of the Scatchard plots showed that dynorphin decreased the number of high affinity-binding site for DHM, while KD of this site was essentially unaltered. Neither Bmax nor KD of low affinity site were much affected. A similar decrease in high affinity Bmax for DADLE was also obtained; however, the recovery was even more rapid. Extra washes of tissue did not significantly increase the binding, but preincubation of tissue in the presence of morphine reversed the dynorphin effect and increased DHM binding significantly to almost control levels. The probable mechanism of dynorphin in decreasing opiate receptor binding is discussed.

KW - Dihydromorphine

KW - Dynorphin-(1-13)

KW - In vitro

KW - In vivo

KW - Opiate binding

KW - [D-Ala,D-Leu]enkephalin

UR - http://www.scopus.com/inward/record.url?scp=0020609312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020609312&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(83)90367-9

DO - 10.1016/0014-2999(83)90367-9

M3 - Article

C2 - 6311575

AN - SCOPUS:0020609312

SN - 0014-2999

VL - 91

SP - 95

EP - 99

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

IS - 1

ER -

Dynorphin-(1-13): The effect of in vivo treatment on opiate bindings in vitro

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this